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Abstract 
Review on plasmablastic lymphoma, with data on 
clinics, and the genes involved. 
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Disease 
Phenotype/cell stem origin 
The cell of origin involved in plasmablastic 
lymphoma (PBL) is the plasmablast. The current 
belief is that the plasmablast is derived from a post-
germinal center B-cell that has undergone 
preterminal differentiation via somatic 
hypermutation and class switching recombination to 
resemble a plasma cell rather than a B-cell (Castillo 
et al., 2008; Hsi et al. 2011). The plasma cell markers 
VS38c, CD38, multiple myeloma oncogene-1 
(MUM1), and CD138 (syndecan-1) seem to be 
almost universally expressed in PBL. There is little 
to no expression of the leukocyte common antigen 
(CD45) or the B-cell markers CD20, CD79a, and 
PAX5. However, there is some distinction in the 
immunophenotype between HIV-positive and HIV-
negative patients with PBL. HIV-positive patients 
seem to show a greater expression of CD20 and 
CD56 compared to HIV-negative patients (Folk et 
al., 2006). The immunophenotypic similarities 
between PBL and plasmablastic or anaplastic plasma 
cell myeloma (PCM) might be challenging for the 
diagnosis (Vega et al., 2005). Therefore, it is 
important to look carefully at additional features that 
are unique and might help in differentiating these 2 
neoplasms. It should be noted that PBL is strongly 
associated with HIV infection and EBER positivity, 
whereas PCM patients present with monoclonal 
paraproteinemia, hypercalcemia, renal dysfunction, 
and lytic bone lesions. For cases that continue to be 
indistinguishable based on immunophenotypic and 
clinical findings, the presence of a MYC (8q24.2) 
translocation, which tends to occur in most PBL 
patients, might be used as a marker in the 
identification of PBL (Taddesse-Heath et al., 2010). 
Epidemiology 
PBL is a rare aggressive B-cell lymphoma strongly 
associated with HIV infection. It makes up 
approximately 2% of all HIV-related lymphomas. 
According to a recent study (Castillo et al., 2015), 
over 600 patients with this lymphoma have been 
reported in a period of 15 years. The majority of 
these patients (63%) were HIV-positive and 28% 
were HIV-negative. Furthermore, according to the 
Castillo and co-authors report, 3% of PBL arose 
from preexisting lymphoproliferative neoplasm via 
transformation, and about 6% arose in patients that 
had undergone solid organ transplant. The disease is 
more common in males than females (4;1). PBL is 
reported to occur at all ages but is very rare in 
children (approximately 3% of all reported cases 
were children, for the most part HIV-positive 
patients). 
Clinics 
There are differences in the clinical presentation of 
PBL in patients with and without HIV infection. 
First of all, the majority of patients with PBL are 
HIV-positive male patients. Interestingly, most 
female patients with PBL do not have HIV, in sharp 
contrast with the male population (Morscio et al., 
2008). 
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Fig.1. Hematoxylin and eosin stained section. The malignant cells are large, with clumped chromatin, smooth nuclear contours, 
and eccentric cytoplasm (plasmacytic appearance). Occasionally, a single prominent "cherry red" nucleolus might be seen in 
these cells. 
 
Most of the HIV-positive patients present with 
extranodal disease particularly affecting the oral 
cavity (Delecluse et al., 1997; Cattaneo et al., 2005), 
followed by the gastrointestinal tract (Luria et al., 
2014), and skin (Jambusaria et al., 2008). 
Furthermore, most patients in this group present with 
advanced clinical stage (stages III or IV) with 
frequent bone marrow involvement. Patients without 
HIV develop PBL at an older age (median age: 55 
years) than the HIV-positive patients (median age: 
42 years). PBL of non-immunocompromized 
patients is more variable as far as sites of 
involvement. However, the oral cavity is still the 
most common presentation. Advanced clinical stage 
and bone marrow involvement is less common in this 
group than in the immunocompromized individuals 
(Morscio et al., 2014). PBL has been reported to 
occur also in solid organ post-transplant patient. The 
majority of these patients received a transplant of the 
heart, followed by the kidney, hematopoietic stem 
cell, lung, liver, and pancreas. Sites of involvement 
in this group of patients typically are the lymph 
nodes, followed by the skin. Approximately 50% of 
these patients had advanced stage disease (Morscio 
et al., 2014). 
Cytology 
The cells involved in PBL are the plasmablasts, 
which are large cells characterized by abundant 
cytoplasm and prominent nucleoli similar to large 
immunoblasts. The plasmablasts features are 
particularly evident in the oral mucosa of HIV-
positive patients. On the other hand, when PBL 
occurs in HIV-negative patients, the neoplastic cells 
resemble differentiated plasma cells with larger 
nuclei and basophilic cytoplasm (Hsi et al. 2011). 
Occasional "cherry red" nucleolus might be seen in 
the plasmablasts. The typical surface markers of 
mature B cells, such as CD20 and CD45, are usually 
down regulated in these cells. Similarly, PAX5 and 
BCL6 are also down regulated. Instead, these cells 
now express cells surface markers typically 
expressed by plasma cells, i.e., VS38c, CD38, 
multiple myeloma oncogene-1 (MUM1), and CD138 
(syndecan-1). 
Prognosis 
The prognosis of patients with PBL is poor with a 
median overall survival (OS) between 8 and 15 
months (Castillo et al., 2008). Specifically, the 
median OS for HIV-positive patients is on average 
10 months, for HIV-negative immunocompetent is 
on average 11 months, and for post-transplant 
patients is on average 7 months (Morscio 2014). 
According to the International Prognostic Index (IPI) 
scoring system for aggressive lymphoma, several 
factors affect the prognosis and survival, such as age, 
performance status, LDH levels, bone marrow 
involvement, number of extranodal sites, and clinical 
stage. Studies, however, are controversial on which 
factor(s) play a bigger part in the prognosis of PBL. 
Some researchers in this field indicated that age, 
LDH levels, and bone marrow involvement do not 
affect outcomes (Castillo et al., 2012), whereas other 
investigators found that age, LDH levels, and Ki-67 
levels ≥80% were the main factors associated with 
adverse outcomes (Schommers et al., 2013). 
Furthermore, HIV-positive patients with a MYC 
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translocation have been found to have a very short 
OS (Taddesse-Heath et al., 2010; Castillo et al., 
2012). Treatment seems to ameliorate the outcome 
versus patients that receive no treatment at all. 
However, currently, the use of cyclophosphamide, 
doxorubicin, vincristine and prednisone (CHOP) is 
considered an inadequate therapy, and current 
guidelines recommend more intensive regimens 
such as infusional etoposide, vincristine, and 
doxorubicin with bolus cyclophosphamide and 
prednisone (EPOCH) (Sparano et al., 2010). As PBL 
is a very aggressive lymphoma, there is a need for 
novel therapies such as those targeted against EBV 
or MYC protein overexpression (Perrine et al., 2007; 
Gebauer et al., 2015; Delmore et al., 2011). 
Cytogenetics 
Cytogenetics morphological 
The most consistent cytogenetic finding in PBL is 
the presence of a MYC (8q24.2) translocation 
(Bogusz et al., 2009; Taddesse-Heath et al., 2010; 
Valera et al., 2010) typically involving one of the 
immunoglobulins, IGH (14q32.3), IGK (2p11.2), or 
IGL (22q11.2). The end result of these  
translocations is the overexpression of MYC. 
Interestingly, all of these IG-MYC translocations 
seem to occur at similar frequency as opposed to 
Burkitt lymphoma where the most common IG-
MYC translocation is the t(8;14)/IGH-MYC, 
followed by t(8;22)/IGL-MYC and t(2;8)/IGK-
MYC.  
The IG/MYC translocations in PBL are frequently 
associated with EBV infection particularly in 
endemic and immunodeficiency-associated tumors, 
similar to what happens with Burkitt lymphoma 
(Dong et al., 2005). 
Additional anomalies 
PBL karyotypes are generally complex. An 
interesting finding that is noticeable in the 
karyotypes of PBL patients, is that some of the 
chromosome abnormalities are similar to those 
observed in PCM, particularly gain of 1q, loss of 1p, 
deletions 13q and/or 17p/TP53, and the 
simultaneous gain of odd-numbered chromosomes, 
specifically +3, +5, +7, +9, +11, and/or +15 
(Taddesse-Heath et al., 2010). Since similar 
karyotypes can also be observed in some aggressive 
(anaplastic) PCM, it is important to take into 
consideration all available clinical information to 
differentiate these two entities. 
 
Fig.2. 60,XX,del(1)(q25),+2,+3,+5,+7,der(7)t(1;7)(q12;q32)x2,+8,t(8;14)(q24.2;q32.3)x2,+9,add(9)(p22)x2,del(9)(q34),+11, 
+14,add(15)(p11.2),der(15)(1qter>q12::?::15p11.2>15qter),ins(16;?)(q12.1;?)x2,+17,add(17)(p11.2)x2,+18,+19,add(19)(p13.3),+
21,add(21)(p11.1),add(21)(p11.2),i(21)(q10),+2mar 
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Genes involved and 
proteins 
The translocations involving MYC occur primarily 
with the immunoglobulin loci, suggesting that MYC 
activation plays a crucial role in the development of 
PBL. It has been shown also that the transcription 
factor PRDM1 (BLIMP1) is highly expressed in 
PBL (Montes-Moreno et al., 2010). One of the 
functions of this gene is to repress genes that 
maintain mature B-cell identity such as PAX5 and 
those that are involved in cell proliferation such as 
MYC. Therefore, the frequent incidence of MYC 
translocation in PBL may be an oncogenic 
mechanism that overcomes the repressor effect of 
BLIMP1. 
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